A5000849008- Bladder and Urothelial Cancer Treatments
- Urinary and Genital Oncology Studies
- Cancer, Lipids, and Metabolism
- Epigenetics and DNA Methylation
- Cancer Cells and Metastasis
- Metabolomics and Mass Spectrometry Studies
- Prostate Cancer Treatment and Research
- Urological Disorders and Treatments
- Tissue Engineering and Regenerative Medicine
- Ferroptosis and cancer prognosis
- Cancer Genomics and Diagnostics
- Cancer Research and Treatments
- Liver physiology and pathology
- Cancer, Hypoxia, and Metabolism
- Esophageal Cancer Research and Treatment
University of Bern
2019-2024
University Hospital of Bern
2021
Bladder Cancer (BLCa) inter-patient heterogeneity is the primary cause of treatment failure, suggesting that patients could benefit from a more personalized approach. Patient-derived organoids (PDOs) have been successfully used as functional model for predicting drug response in different cancers. In our study, we establish PDO cultures BLCa stages and grades. PDOs preserve histological molecular parental tumors, including their multiclonal genetic landscapes, consistently share key...
Little is known about the relationship between metabolite profile of plasma from pre-operative prostate cancer (PCa) patients and risk PCa progression. In this study we investigated association metabolites biochemical-, local- metastatic-recurrence, with aim improving patient stratification.We conducted a case-control within cohort recruited 1996 2015. The age-matched primary cases (n = 33) were stratified in low risk, high without progression as defined by National Comprehensive Cancer...
In intermediate-risk non-muscle invasive bladder cancer (NMIBC) clinical guidelines suggest an adjuvant instillation with a chemotherapeutic agent. However, the agent and regimen are not clearly defined. Worldwide, less than 15% of patients receive this instillation. We recently developed pipeline for generation patient derived organoids (PDO) in NMIBC. phase II trial, we aim to use our vitro select most effective drug NMIBC patients.Patients first diagnosis that directed transurethral...
Abstract Recent research suggests the potential categorization of bladder cancer (BLCa) patients into molecular subtypes to aid in selection appropriate treatment strategies, be it conventional, targeted, or a combination thereof. However, practical implementation classifiers has faced obstacles due intricate nature gene regulation, tumor heterogeneity, and challenges related sampling caused by substantial stromal infiltration multifocality. Hence, there is pressing need for more...
Abstract Bladder Cancer (BLCa) inter-patient heterogeneity is considered the primary cause of tumor reoccurrence and treatment failure, suggesting that BLCa patients could benefit from a more personalized approach. Patient-derived organoids (PDOs) have been successfully used as functional model for predicting drug response in different cancer types. In our study, we established PDO cultures stages. PDOs preserve histological molecular parental tumors, including their multiclonal genetic...
Abstract Bladder Cancer (BLCa) inter-patient heterogeneity is the primary cause of treatment failure, suggesting that patients could benefit from a more personalized approach. Patient-derived organoids (PDOs) have been successfully used as functional model for predicting drug response in different cancers. In our study, we established PDO cultures BLCa stages. PDOs preserve histological and molecular parental tumors (PT), including their multiclonal genetic landscapes, consistently share key...
Abstract Background: In intermediate risk non-muscle-invasive bladder cancer (NMIBC) clinical guidelines suggest an adjuvant instillation with a chemotherapeutic agent. However, the agent and regimen are not clearly defined. Worldwide, less than 15% of patients receive this instillation. We recently developed pipeline for generation patient derived organoids (PDO) in NMIBC. phase II trial, we aim to use our vitro select most effective drug NMIBC patients. Methods: Patients first diagnosis...
Abstract Introduction: Interpatient heterogeneity is one of the causes treatment failure in bladder cancer (BLCa) patients, who would therefore profit from tailor-made therapies. Toward direction precision medicine, patient-derived organoids (PDOs), which retain parental tumor (PT) features, have been successfully tested different types and shown to predict patients’ responses. Therefore, our study aimed explore ability BLCa PDOs PT features determine patient drug sensitivity. We correlated...
You have accessJournal of UrologyCME1 May 2022MP06-07 APPLICATION OF BLADDER CANCER PATIENT-DERIVED ORGANOIDS AS PRE-CLINICAL MODEL FOR PERSONALIZED MEDICINE Martina Minoli, Mirjam Kiener, Thomas Cantore, Tarcisio Fedrizzi, Paola Gasparini, Francesca Demichelis, George N. Thalmann, Roland Seiler-Blarer, and Marianna Kruithof-de Julio MinoliMartina Minoli More articles by this author , KienerMirjam Kiener CantoreThomas Cantore FedrizziTarcisio Fedrizzi GaspariniPaola Gasparini...
You have accessJournal of UrologyCME1 May 2022MP06-08 SINGLE-CELL SEQUENCING OF PARENTAL BLADDER CANCER AND SUBSEQUENT ORGANOIDS REVEALS DIFFERENTIAL CELL PRESERVATION Roland Seiler, Martina Minoli, Franziaks Singer, Anne Bertolini, Ulrike Menzel, Christian Beisel, and Marianna Kruithof-de Julio SeilerRoland Seiler More articles by this author , MinoliMartina Minoli SingerFranziaks Singer BertoliniAnne Bertolini MenzelUlrike Menzel BeiselChristian Beisel JulioMarianna View All Author...
You have accessJournal of UrologyBladder Cancer: Basic Research & Pathophysiology III (MP66)1 Sep 2021MP66-17 BLADDER CANCER: PATIENT-DERIVED ORGANOIDS AS A TOOL FOR PRECISION MEDICINE Martina Minoli, Mirjam Kiener, Tarcisio Fedrizzi, Paola Gasperini, Francesca Demichelis, George Niklaus Thalmann, Roland Seiler-Blarer, and Marianna Kruithof-de Julio MinoliMartina Minoli More articles by this author , KienerMirjam Kiener FedrizziTarcisio Fedrizzi GasperiniPaola Gasperini DemichelisFrancesca...